Truist Financial
FTH

Truist Financial’s Faeth Therapeutics FTH Stock Holding History

Truist Financial’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-997
Closed -$45K – 2662
2022
Q2 		$45K Sell
997
-1,525
-60% -$57.1K ﹤0.01% 2585
2022
Q1 		$117K Hold
2,522
– – ﹤0.01% 2596
2021
Q4 		$293K Sell
2,522
-997
-28% -$149K ﹤0.01% 2381
2021
Q3 		$740K Buy
+3,519
New +$641K ﹤0.01% 1784

Other funds holding FTH

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Truist Financial's FTH Position: Q3 2022 in Review

Truist Financial sold out of Faeth Therapeutics (FTH) in Q3 2022, closing a stake of 997 shares — an estimated $45K sold.

Truist Financial first reported a position in FTH in Q3 2021 and held it in 4 quarters. The position peaked at $740K in Q3 2021. 30 funds tracked by Wall St. Rank hold FTH as of Q3 2022.

  • Truist Financial reported no remaining Faeth Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Truist Financial sold 997 Faeth Therapeutics shares in Q3 2022, an estimated $45K.
  • Truist Financial first reported a position in Faeth Therapeutics in Q3 2021 and held it in 4 quarters.
  • Truist Financial's Faeth Therapeutics position peaked at $740K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2022.

Based on Truist Financial's 13F filing for Q3 2022, filed 26 Oct 2022.